Well, it might take 4 years but both my favorites finally hit it big in the last 12 months: Old IZP is now on the TSE 300 and hit $8+ last year and old CYTO hit $21: TIME and EFFORTS:
Inflazyme Pharmaceuticals Ltd - News Release
Inflazyme chosen to list in the TSE 300
Inflazyme Pharmaceuticals Ltd IZP
Shares issued 48,011,7462001-01-22 close $3.9
Tuesday Jan 23 2001News Release
Mr. Jeffrey Bacha reports
Inflazyme Pharmaceuticals has been selected by Standard and Poors (S&P) to be added to the Toronto Stock Exchange 300 composite index (TSE 300). This inclusion will become effective as of the close of business on Tuesday, Jan. 23, 2001.
"We are very pleased to be selected for inclusion in the TSE 300 composite endex," said Ian McBeath, Inflazyme's president and chief executive officer. "This reflects the overall market growth of our company and the hard work of our scientific teams in bringing forward our pipeline of novel small molecule anti-inflammatory compounds."
(c) Copyright 2001 Canjex Publishing Ltd. canada-stockwatch.com
old url (better for printing)
and yesterday:
Inflazyme Pharmaceuticals Ltd - News Release
Inflazyme and Aventis expand collaboration
Inflazyme Pharmaceuticals Ltd IZP
Shares issued 48,011,746 2001-01-19 close $3.61
Monday Jan 22 2001 News Release
Mr. Ian McBeath reports
Inflazyme Pharmaceuticals has expanded its continuing collaboration with Aventis Pharma, Inc. for the research and development of anti-inflammatory therapeutics from Inflazyme's IPL576 series of novel small-molecule compounds.
Inflazyme announced in Stockwatch Dec. 22, 2000, that it had received regulatory approval for IPL576,092, the lead molecule from its IPL576 series, to commence phase II asthma clinical trials in the United Kingdom.
The new agreement covers two additional molecules: IPL550,260 and IPL512,602, which are based on research related to the company's IPL576 series.
Inflazyme and Aventis will contribute jointly to the development of both compounds. Aventis will undertake cGMP manufacturing, formulation and certain preclinical studies. Inflazyme will be responsible for toxicology and certain other preclinical studies. In return for their contribution, Aventis has the right to choose one of the two compounds for inclusion into the May, 1999, licence and research collaboration agreement between Inflazyme and Aventis. Inflazyme will retain all rights to the other compound.
The May, 1999, licence and research collaboration agreement covers the co-development of Inflazyme's IPL576 series for the treatment of asthma and respiratory diseases and the development of Aventis' H1/NK1 dual antagonist for allergies. Inflazyme has to date received $16-million (U.S.) in cash and equity investments and may receive up to an additional $75-million (U.S.) in milestone payments. Inflazyme will receive double digit royalties on future sales of products developed under the agreement. Aventis has a right of first refusal to license additional products from Inflazyme's IPL576 series, for other indications, on new commercial terms to be agreed.
Ian McBeath, president and chief executive officer of Inflazyme, said today: "The expansion of our collaboration continues to endorse the strong relationship that exists between Inflazyme and Aventis. With Aventis's increased commitment to the development of our IPL576 series, we are able to broaden and accelerate the development of our product pipeline. This is a very creative arrangement; having Aventis take on much of the costs of the program will have a favourable impact on our cash burn in the near term, with both companies each ending up with a potential new product."
John Zawad, vice-president, technology licensing and alliances for Aventis, said: "This new agreement to jointly co-develop these two compounds truly strengthens the existing partnership between Aventis and Inflazyme. We have been impressed by the progress Inflazyme scientists have made to date in the development of both the IPL576 series and the H1/NK1 dual antagonists and especially the success in moving IPL576,092 into phase II clinical trials for asthma. This arrangement offers us the potential for multiple product opportunities."
"We plan to review these new compounds in a broad range of anti- inflammatory diseases," said Mr. McBeath. "With Aventis's assistance we expect to be in a position to initiate clinical trials before the end of the year."
About the IPL576 series
The IPL576 series are novel synthetic chemical compounds based on a molecule originally isolated from a sea sponge by researchers at the University of British Columbia and the University of Alberta. Preclinical research has demonstrated that molecules from the IPL576 series have a significant effect on mediators of inflammation in vitro and in standard preclinical in vivo studies. These preclinical studies also demonstrate that compounds from the IPL576 series may have the efficacy of inhaled glucocorticoids without the related side effects.
IPL576,092 is currently undergoing human clinical trials for the treatment of asthma. In December, 2000, Inflazyme announced that the company had received approval to initiate phase II clinical trials with IPL576,092 as a potential oral therapy for asthma. The company plans to initiate these studies in early 2001 and expects to receive results before the end of the year.
Aventis Pharma AG is the pharmaceutical company of Aventis. Aventis Pharma is dedicated to treating and preventing human disease through the discovery, development, manufacture and sale of innovative pharmaceutical products aimed at satisfying unmet medical needs. Aventis Pharma focuses on important therapeutic areas such as cardiology, oncology, infectious diseases, arthritis, allergies and respiratory disorders, diabetes and central nervous system disorders. Aventis Pharma has its corporate headquarters in Frankfurt, Germany. Aventis Pharma encompasses Aventis Pasteur, a world leader in vaccines based in Lyon, France, and Aventis Behring, a world leader in therapeutic proteins headquartered in King of Prussia, Penn., U.S.
WARNING: The company relies upon litigation protection for "forward-looking" statements.
(c) Copyright 2001 Canjex Publishing Ltd. canada-stockwatch.com
Chucka-congrats |
